Research and Development – BiotechReality – Information Intelligence System for Biopharma

BOSTON — Nov. 11, 2025 — In a significant move to accelerate precision medicine, AI-driven analytics leader SOPHiA GENETICS (NASDAQ: SOPH) and genomic sequencing innovator Complete Genomics announced a new collaboration today. The collaboration, which was announced at the Association for Molecular Pathology (AMP) Annual Meeting, will combine top-notch oncology applications with a high-throughput sequencing platform to provide laboratories all over the world with a simplified sample-to-report solution. The collaboration will co-market two renowned Memorial Sloan Kettering Cancer Center (MSK) tests MSK-IMPACT® (for solid tumors) and MSK-ACCESS® (for liquid biopsy) powered by the SOPHiA DDM™ artificial intelligence platform, on Complete Genomics' newly launched DNBSEQ-T1+ sequencing system. With this integration, the two businesses' collaboration has significantly grown and they are making a bold move into the precision oncology research market. The main objective is to enable drug developers, cancer centres, and decentralised labs by offering a highly accurate, scalable, and economical workflow for thorough genomic profiling. Read More: Genomics Research Can be Automated by Artificial Intelligence A Powerful and Accessible Solution Three essential elements are combined in this partnership: Complete Genomics' potent sequencing equipment, SOPHiA's sophisticated AI analytics, and MSK's thoroughly validated cancer assays. Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling, By combining MSK's rigorously validated assays, SOPHiA GENETICS' robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers. Rob Tarbox The Technology Behind the Partnership Whole Genomics DNBSEQ-T1+: This new platform offers Q40-level accuracy thanks to its proprietary DNBSEQ technology. It allows each flow cell to function independently and provides an optimised throughput of 500 million to 2 billion reads per flow cell. Labs are able to run a 24-hour paired-end 150bp cycle because of this flexibility. Up to 60 tumor-normal sample pairs for tissue or 16 tumor-normal sample pairs for liquid biopsy can be processed by a single T1+ flow cell at full capacity. SOPHiA DDM™ Platform: The SOPHiA DDM™ Platform is a technology-neutral analytics tool that uses cutting-edge AI algorithms to calculate, standardise, and examine intricate medical data from multiple sources. Read More: Next Generation Sequencing (NGS) and its application in genomics The companies claim that when compared to similar sequencing systems, a joint evaluation of the integrated system showed highly concordant variant calls and allele frequencies. Reduced turnaround time, less background noise, and smooth integration with current SOPHiA DDMTM workflows were further benefits of the combined workflow. About SOPHiA GENETICS Dedicated to creating applications for data-driven medicine, SOPHiA GENETICS is a world leader in AI-driven precision medicine. Numerous healthcare organisations trust its SOPHiA DDMTM platform and associated solutions. Information: SOPHiA GENETICS Last Modified:

Tag: Research and Development

SOPHiA GENETICS and Complete Genomics Partner to Integrate AI Oncology Assays with New Sequencing Platform

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment